A Phase III study shows that a 40mg/1mL dose of Teva's (TEVA) Copaxone given three times a week...


A Phase III study shows that a 40mg/1mL dose of Teva's (TEVA) Copaxone given three times a week significantly reduces relapse rates at 12 months in patients with multiple sclerosis, and that the drug is safe and tolerable at this measurement. The current approved dose for Copaxone is 20mg/1mL once a day. (PR) Meanwhile, Teva has signed a five-year deal to commercialize Illumina's (ILMN) Verifi non-invasive pre-natal test in Israel. The test can identify chromosomal abnormalities in fetuses. (PR)

From other sites
Comments (1)
  • User 11759321
    , contributor
    Comment (1) | Send Message
     
    Would approval of this drug have any impact on the expiration of TEVA's patent on Copaxone (I.e. - would it be patented separately and, if so, what kind of life would the new patent have?)? Has potential market for the increased dosage been assessed?
    1 Jul 2013, 05:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs